Sandoz' Hexal Wins Landmark German Case Over Desloratadine Switch
Sandoz, through its Hexal subsidiary, has won an important case against the German Ministry of Health over a delayed prescription-to-OTC switch of desloratadine, which shows European Union Member States have got the authority to switch at a national level centrally authorized drugs.
You may also be interested in...
The German Medicines Manufacturers´ Association
Elmar Kroth, scientific director of the German Medicines Manufacturers´ Association, the BAH, talks exclusively to HBW Insight about prescription-to-OTC switching in Germany and the association’s efforts to improve this process.
“With so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed,” explains the UK Food Standards Agency, in response to confusion within the country's CBD industry.